Mechanism of Action

Mechanism of Action (MOA) refers to the specific molecular and biochemical pathway through which a pharmacological agent exerts its therapeutic or physiological activity. MOA characterization includes identifying the target receptor or enzyme, the binding kinetics, the G-protein or kinase coupling, the secondary messengers (e.g., cAMP, IP3, Ca2+), and the resulting cellular response.

Understanding a peptide's MOA allows pharmacologists to anticipate drug interactions, side effects, and clinical synergy. For example, understanding that semaglutide stimulates beta-cell insulin secretion only during elevated glucose explains why it carries a low intrinsic risk of hypoglycemia.

Mechanism claims are a staple of peptide marketing: a product “upregulates growth factors” or “activates repair pathways”. A plausible mechanism seen in cells or animals is not evidence that a peptide helps people. For BPC-157, a 2025 systematic review reported preclinical findings on growth hormone receptor expression and pathways linked to blood vessel growth, yet found only one small clinical study and no clinical safety data.

For approved peptides, a well-described mechanism helps explain both benefits and side effects. GLP-1 increases insulin and reduces glucagon secretion, slows gastric emptying and reduces food intake. These actions underlie the glucose-lowering and weight effects of GLP-1 receptor agonists, and the slowing of gastric emptying helps explain why nausea is among their most common side effects.

Mechanism also explains drug design. Native GLP-1 is broken down within minutes by the enzyme DPP-4, so two strategies emerged: degradation-resistant GLP-1 receptor agonists, and DPP-4 inhibitors that protect the body’s own GLP-1. Understanding the mechanism shows why these classes act differently even though both work through the incretin system.

“A known mechanism proves the drug works”

A mechanism describes how a substance could produce an effect; it does not show that the effect is large enough, lasting enough or safe enough to matter in people. Many compounds with convincing mechanisms fail in clinical trials. Only well-designed human studies can show real benefit, which is why mechanism sits early in the chain of evidence.

“Peptides with the same mechanism are interchangeable”

Drugs acting on the same receptor can differ greatly in potency, duration and side effects. Semaglutide binds the GLP-1 receptor about three times less tightly than liraglutide in laboratory tests, yet acts far longer because of stronger albumin binding and resistance to breakdown. Sharing a mechanism does not mean sharing a profile.

“If the mechanism is unclear, the evidence must be weak”

Clinical benefit can be well established before every step of a mechanism is understood, and research on GLP-1 continues to map the cell types and pathways involved. The strength of evidence for a treatment rests mainly on the quality of human outcome data, not on how complete the mechanistic story is.

What is the mechanism of action of semaglutide?

Semaglutide is a GLP-1 receptor agonist. It activates the same receptor as the natural hormone GLP-1, increasing glucose-dependent insulin release, reducing glucagon, slowing gastric emptying and reducing appetite. Its structure was modified with amino acid substitutions and a fatty acid chain so it binds albumin and resists breakdown, giving a much longer action than native GLP-1.

What is the difference between mechanism of action and pharmacodynamics?

Mechanism of action is the specific molecular interaction through which a drug works, such as activating a receptor or blocking an enzyme. Pharmacodynamics is broader: it describes the drug’s effects on the body, including how effect size changes with concentration, onset, duration and side effects. Mechanism explains why the pharmacodynamic effects occur.

What is the mechanism of action of BPC-157?

It has not been established in humans. Preclinical studies suggest effects on growth hormone receptor expression, blood vessel growth and inflammatory signalling, according to a 2025 systematic review, but these findings come almost entirely from cell and animal experiments. BPC-157 is not FDA-approved, and its proposed mechanisms remain hypotheses rather than confirmed clinical pharmacology.

Why does knowing a drug’s mechanism matter for safety?

A known mechanism helps predict side effects, drug interactions and who should avoid a medicine. For example, because GLP-1 receptor agonists slow gastric emptying, gastrointestinal effects are expected and are monitored in trials. With a poorly understood mechanism, unexpected effects are harder to anticipate and harder to recognise when they occur.